Nyrada Receives US Patent Notice of Allowance for Xolatryp Globally
Nyrada secures US patent notice of allowance for Xolatryp®, strengthening global IP position
Nyrada Inc. (ASX: NYR) has received a notice of allowance from the United States Patent and Trademark Office for its patent application covering the composition of matter of Xolatryp®. Subject to payment of the issue fee, the granted patent will provide 20 years of intellectual property protection from the September 2024 filing date. The US application forms part of a broader global patent portfolio filed across Australia, Europe, and Japan.
James Bonnar, CEO and Managing Director
“The receipt of this notice of allowance is a significant milestone for Nyrada and validates the novelty and inventiveness of Xolatryp. Robust intellectual property protection is fundamental to realising the full commercial value of Xolatryp, and this patent strengthens our position as we advance clinical development.”
When big ASX news breaks, our subscribers know first
What a composition of matter patent means for Xolatryp
A composition of matter patent is widely regarded as the strongest form of intellectual property protection available in the pharmaceutical industry. Rather than protecting a specific use or manufacturing process, it covers the chemical structure of a compound itself, giving the holder broad defensive rights over the asset.
For Xolatryp, this means the patent protects against the unauthorised manufacture, use, sale, or import of Xolatryp without Nyrada’s approval. This scope of protection is significant: it cannot be circumvented simply by developing a different application for the same molecule.
The 20-year term from the filing date is particularly meaningful for a clinical-stage biotech. If development proceeds on schedule, this window is designed to preserve commercial exclusivity well through and beyond a potential market launch, providing the time needed to realise returns on clinical investment. For investors, a composition of matter patent is a core pillar of commercialisation value, supporting any future licensing, partnering, or out-licensing discussions.
A global IP strategy across key markets
Nyrada’s patent filings span the following jurisdictions:
- United States (notice of allowance received)
- Australia
- Europe
- Japan
The US represents a particularly critical market given the scale of the cardiovascular therapeutics sector, making this notice of allowance a commercially meaningful step beyond its legal significance.
Xolatryp’s clinical momentum and the unmet need it targets
Addressing a critical gap in cardiac care
Xolatryp is being developed to treat ST-Elevation Myocardial Infarction (STEMI) and ischemia reperfusion injury in patients undergoing percutaneous coronary intervention (PCI). This is the tissue damage that occurs when blood flow is restored to the heart after a blockage, paradoxically causing further injury at the cellular level.
The market opportunity here is notable. As stated in the announcement, “there are currently no approved therapies that directly address ischemia and reperfusion injury.” This is not a crowded field with entrenched competitors. Xolatryp is targeting a condition that affects a large patient population globally, with no existing pharmacological standard of care directed at the reperfusion injury mechanism itself.
From Phase I to Phase IIa — where Xolatryp stands today
Xolatryp’s clinical development has progressed through the following stages:
- Phase I completed — assessed safety, tolerability, and pharmacokinetics; successfully completed first-in-human trial.
- Phase IIa commenced — assessing safety and exploring preliminary efficacy in STEMI patients undergoing PCI (PROTECT-MI trial).
At its core, Xolatryp is a small-molecule inhibitor of TRPC3/6/7 channels designed to limit excessive Ca²⁺ entry linked to multiple disease pathologies. In simple terms, TRPC3/6/7 channels are proteins on cell surfaces that regulate calcium flow. When these channels are overactive during a cardiac event, excess calcium floods the cell and drives injury. Xolatryp is designed to block this process.
Beyond cardiology, preclinical efficacy signals have been observed in neuroprotection models, including traumatic brain injury and stroke studies. These findings indicate the potential for a broader indication pipeline beyond the current STEMI focus.
| Stage | Status | Focus | Key Detail |
|---|---|---|---|
| Preclinical | Completed | Cardioprotection & neuroprotection | Multiple animal model studies |
| Phase I | Completed | Safety, tolerability, PK | First-in-human; successful |
| Phase IIa | Ongoing | Safety & preliminary efficacy | STEMI patients undergoing PCI |
The next major ASX story will hit our subscribers first
What this milestone means for Nyrada’s investment case
The notice of allowance from the United States Patent and Trademark Office is more than an administrative formality. A USPTO allowance signals that an independent examiner has assessed the compound and found it to meet the legal thresholds of novelty and inventiveness, lending external credibility to the Xolatryp asset.
The timing adds further weight. A strengthened IP position arriving while the Phase IIa PROTECT-MI trial is actively enrolling creates a convergence of positive signals. Strong IP coverage underpins every downstream pathway, whether Nyrada pursues independent commercialisation, a licensing arrangement, or a strategic partnering deal.
Key investment-relevant takeaways from this announcement include:
- USPTO notice of allowance received for Xolatryp composition of matter patent
- 20-year protection term from the September 2024 filing date
- Global portfolio spanning the US, Australia, Europe, and Japan
- Phase IIa (PROTECT-MI) actively enrolling STEMI patients
- No approved therapies currently address ischemia reperfusion injury, positioning Xolatryp against a clear unmet medical need
With Phase IIa data expected to mature and a formalised US patent on the horizon, Nyrada’s near-term clinical and commercial roadmap carries a number of catalysts worth monitoring closely.
Don’t Miss the Next ASX Healthcare Breakthrough
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis. Over 20,000 subscribers already rely on it to stay ahead of the market. Click the “Free Alerts” button at StockWire X to make sure the next major announcement lands in your inbox the moment it breaks.